Evidence map›Paper›PMID 36431983›Full record

ArticleMolecules (Basel, Switzerland)2022

Ethyl Acetate Extract from

Wenqian Yang, Fei Shao, Jiexin Wang, Tong Shen, Yu Zhao, Xueyan Fu, Liming Zhang, Hangying Li

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Preparation ofBioengineering (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wenqian YangCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Fei ShaoCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Jiexin WangCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Tong ShenCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Yu ZhaoCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Xueyan FuCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Liming ZhangCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Hangying LiCollege of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
Ningxia Medical University · CN

Funding

Field project Foundation of Ningxia Medical University XT2020022Field project Foundation of the Ningxia Hui Autonomous Region 2021BEB04060Project supported by the National Natural Science Foundation of China 22267017
6 · The paper itself

Abstract

backgroundImmunological liver injury (ILI) is a common liver disease and lacks potent drugs for treatment. PURPOSE: To investigate the effect that ethyl acetate extract of

methodsThe chemical components of AaEA were studied by LC-MS. In animal experiments, the positive control group was administrated diammonium glycyrrhizinate (DIG, 100 mg/kg), while different doses of AaEA groups (AaEA-H, AaEA-M, AaEA-L) were pretreated with AaEA 2.00, 1.00, and 0.50 g/kg, respectively, by intragastric for seven days, once every day. Then, ConA (12.00 mg/kg) was used through tail intravenous injection to establish the ILI model. The blood samples and livers were collected to test the degree of liver dysfunction, inflammation, oxidative stress, histopathological changes, and cell apoptosis. Real-time PCR and Western blotting analysis were used to explain the mechanism of regulating Bax/Bcl-2 and TLR4/MyD88/NF-

resultsThe way in which AaEA prevents liver damage in immunological liver injury (ILI) mice caused by ConA was investigated for the first time. Pretreatment with AaEA reduced the expression of ALT, AST, and inflammatory factors (TNF-

conclusionAaEA can work against ConA-induced ILI in mice by regulating Bax/Bcl-2 and TLR4/MyD88/NF-

Indexed as

ArtemisiaLiver DiseasesAcetatesAnimalsbcl-2-Associated X ProteinConcanavalin AMiceMyeloid Differentiation Factor 88NF-kappa BSignal TransductionToll-Like Receptor 4Acetatesbcl-2-Associated X ProteinConcanavalin Aethyl acetateMyd88 protein, mouseMyeloid Differentiation Factor 88NF-kappa BTlr4 protein, mouseToll-Like Receptor 4Artemisia argyi Lévl. et Vant.Bax/Bcl-2 and TLR4/MyD88/NF-κBdietary plantfood therapyimmunological liver injuryphytochemistry

Identifiers

PMID36431983
PMCPMC9693258
OpenAlexW4309315601

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.